Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374417 | 1.00 | S1PR1 (0.43) | S1PR1EGFRFGFR1PRCPMEN1 | |
| SCHEMBL13855370 | 1.00 | S1PR1 (0.43) | S1PR1EGFRFGFR1PRCPMEN1 | |
| SCHEMBL13855374 | 0.89 | EGFR (0.53) | S1PR1EGFRFGFR1PRCPBRD4 | |
| SCHEMBL582850 | 0.89 | EGFR (0.53) | S1PR1EGFRFGFR1PRCPBRD4 | |
| SCHEMBL582849 | 0.89 | EGFR (0.53) | S1PR1EGFRFGFR1PRCPBRD4 | |
| SCHEMBL374628 | 0.82 | LCK (0.50) | S1PR1EGFRFGFR1BRD4MAPK7 | |
| SCHEMBL374627 | 0.82 | LCK (0.50) | S1PR1EGFRFGFR1BRD4MAPK7 | |
| SCHEMBL13855372 | 0.82 | LCK (0.50) | S1PR1EGFRFGFR1BRD4MAPK7 | |
| SCHEMBL374169 | 0.81 | EGFR (0.39) | S1PR1EGFRFGFR1PRCPMEN1 | |
| SCHEMBL374170 | 0.81 | EGFR (0.39) | S1PR1EGFRFGFR1PRCPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | claimed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | claimed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | S1PR1 1157/4885EGFR 397/4885FGFR1 683/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | S1PR1 1157/4885EGFR 397/4885FGFR1 683/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | S1PR1 1157/4885EGFR 397/4885FGFR1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.